Foundayo™ (orforglipron)
- Small-molecule GLP-1, approved April 2026
- Once daily, no injections, no refrigeration
- ATTAIN-1 results published in NEJM
- At PinwellRx: $549/mo, never discounted
Wegovy® tablets (oral semaglutide)
- Brand semaglutide as a once-daily tablet
- Taken with water on an empty stomach
- Semaglutide evidence: STEP-1, NEJM
- At PinwellRx: $499/mo, never discounted
Compounded oral semaglutide
- Pharmacy-prepared daily tablet, taken with water
- Not FDA-reviewed for safety or effectiveness
- Brand trial results do not apply to it
- At PinwellRx: $279/mo when prescribed
Compounded oral tirzepatide
- Pharmacy-prepared daily tablet, taken with water
- No FDA-approved tirzepatide pill exists
- No published bioavailability data
- At PinwellRx: $329/mo when prescribed
Is a pill as effective as an injection?
It depends on the product, and the honest answer lives in the published data. Foundayo’s ATTAIN-1 results and Wegovy’s STEP-1 results were each reported in NEJM for those specific FDA-approved products. Compounded tablets have no equivalent published trials, so no one can honestly claim they match. Your clinician weighs the evidence, your history, and your preferences.
Why would someone choose a compounded tablet?
Usually price and needle avoidance. Compounded tablets cost roughly half of the branded pills at PinwellRx. The trade-off is the absence of FDA review - FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. That trade-off is exactly what your clinician helps you think through.
How do I find out which one I qualify for?
One intake covers all of them. A licensed clinician reviews your health history and, when appropriate, prescribes the option that fits - you never pick a drug from a menu. You see the exact price before you pay, and you get a full refund if nothing is prescribed.
Find the option that fits you
One intake, every oral option considered, one clinician decision - and your price before you pay.
- NEJM - ATTAIN-1 trial of orforglipron (Foundayo)
- NEJM - STEP-1 trial of semaglutide (Wegovy)
- Drugs@FDA - approved drug products
- FDA - Human Drug Compounding